Elanco Animal Health Third Quarter 2026 Results - ELANCO ANIMAL HEALTH INC

Financial Performance:

• Reported revenue grew 11% to $1.265 billion, driven by a 9% organic constant currency growth (5% volume, 4% price).
• Adjusted EBITDA reached $243 million, a 23% increase year-over-year, while Adjusted EPS rose 42% to $0.27.
• Gross margin expanded by 300 basis points to 56.1%, supported by favorable mix, pricing, and manufacturing efficiencies from the "Elanco Ascend" productivity initiative.
• Net leverage dropped to 2.9 times the trailing twelve-month earnings, surpassing the sub-3x target ahead of schedule.
• Free cash flow totaled $362 million year-to-date, tracking ahead of the $1 billion cumulative target by 2028.
• Debt reduction accelerated with $216 million paid down in Q3, bringing the year-to-date total reduction to $317 million.

Guidance and Future Outlook:

• Full-year 2026 organic constant currency revenue guidance raised to ~8% (previously 6-7%), with adjusted EBITDA guidance increased by $35 million (17% growth midpoint).
• Full-year 2026 adjusted EPS guidance raised to $1.17–$1.20 (midpoint), reflecting a 26% growth.
• Reaffirmed long-term "annual algorithm" for 2027 and beyond: mid-single-digit organic revenue growth, high-single-digit adjusted EBITDA growth, and low-double-digit adjusted EPS growth.
• 2027 outlook anticipates challenges from Q1 comparisons (including the loss of Costco distribution) and potential farm animal cyclicality, offset by new product launches like Bofrena.
• Full-year innovation revenue target raised to $1.275 billion, with the "Big Six" innovation portfolio ahead of pace to double by 2028.

Business Segments and Product Lines:

• U.S. Pet Health: Grew 13% organically, led by Vet clinic sales of Zanrelia and Cordelio Quattro and strong price/mix contributions.
• International Pet Health: Achieved 17% organic growth driven by Zanrelia (approaching blockbuster status) and ADTAB.
• Farm Animal: U.S. business grew 7% (10% including acquisition); International grew 1% organically. Ruminants remained the fastest-growing species segment.
• Key Innovations: Zanrelia sales doubled in the U.S. quarter; Cordelio Quattro surpassed Seresto as the largest U.S. pet health product by trailing four-quarter revenue; Bofrena moved from phased to full-scale national launch in Q1 2027.
• Pipeline: No attrition in the 15+ project pipeline; confident in delivering 5-6 blockbuster potential innovations by 2031.

Market and Competitive Landscape:

• Market Share: Zanrelia and Cordelio Quattro achieved record U.S. market shares in September; Zanrelia gained 10 share points in Europe in H1 2026.
• Competition: Acknowledged time-bound promotional tactics by competitors (primarily in general practices) but emphasized these do not fundamentally impact Elanco's share gain trajectory.
• Consumer Demand: Pet health spend remains resilient; 93% of pet owners maintained or increased spending in the past three months according to a recent survey.
• Channel Dynamics: Successfully navigating shift to omni-channel; retail sales impacted by inventory drawdowns but underlying consumption trends positive.

Risks and Challenges:

• Competitive Dynamics: Potential for short-term sales timing shifts due to competitor pricing/promotions, though management views the overall competitive backdrop as responsible.
• Distribution Loss: Anticipated negative impact on Q1 2027 retail sales due to the non-renewal of the Costco agreement, expected to be offset by new distribution partners.
• Farm Cyclicality: Regional farm cycles (dairy oversupply, swine breakeven struggles) may cause quarter-to-quarter volatility in the Farm Animal segment.
• Inflation & Margins: Potential gross margin headwinds from dilutive "front-of-house" volume growth and persistent inflationary costs, though "Elanco Ascend" initiatives aim to offset these.
• Supply Chain: Bofrena faced initial supply constraints but manufacturing expansion is complete; expected to be a major growth driver in 2027.

Management Commentary and Tone:

• Management expressed high confidence and optimism, describing Q3 as an "outstanding" quarter and the "best year in R&D history."
• Emphasized a strategy of growth via medical differentiation ("Best Medicine") rather than price competition, noting low customer churn to competitors.
• Reiterated commitment to the "Growth, Innovation, Cash" priorities, with the sub-3x leverage milestone unlocking new capital allocation flexibility.
• Tone was assertive regarding the durability of the animal health market and the ability to win share despite broader economic pressures.

Analyst Questions and Answers:

• Margins: Management attributed Q3 margin expansion to pricing, mix, and manufacturing improvements; confirmed "Elanco Ascend" benefits will continue to drive gross margin and EBITDA improvement through 2030.
• Costco: Clarified that the non-renewal impacts Q1 2027 but will be net-positive annually due to new retail partnerships; confirmed no unusual stocking/destocking in Q3.
• Competition: Clarified that competitive promotions are "time-bound" and shift volume temporarily without altering long-term share trends; noted that corporate accounts remain stable.
• Product Launches: Zanrelia penetration in clinics rose to 19,000 (two-thirds of U.S. base); Bofrena launch strategy involves immediate ordering by sales reps ahead of a formal Q1 launch.
• Pricing: Q3 pricing was 4% (5% in pet health); management expects pricing to settle at 2-3% historically for Q4 and 2027 as launch offers scale back.

Other Key Points:

• Acquired HV (animal health) on April 30, contributing approximately 1% to growth and strengthening the global ruminant position.
• Launched a proprietary AI-driven regulatory submission tool in R&D to accelerate speed to market.
• Held a first-ever supplier day with 70+ partners to collaborate on procurement and inflation offset strategies.
• Seresto retail sales were temporarily impacted by retailer inventory drawdowns, though year-to-date consumption remains slightly positive.
• U.S. retail growth in 2027 is expected to remain resilient despite the Costco loss, driven by new distribution points and omni-channel leadership.